Monographie - Fluorouracil

Laatste update :
19/11/2024

Fluorouracil

Molecuulstructuur

Merknamen in verschillende landen

Handelsnamen zijn slechts een indicatie; de samenstelling van hulpstoffen kan per land variëren afhankelijk van de fabrikant

Acoflut	Mexico
Adrucil	USA
Eurofluor	Duitsland
Fivocil	Indië
Fivoflu	Indië, Mexico
Fluorouracil	België, Brazilië, Canada, Denemarken, Finland, Griekenland, Groot Britannië, Hongarije, Italië, Joegoslavië, Nederland, Noorwegen, Oostenrijk, Polen, Portugal, Spanje, Turkije, USA, Zuid-Afrika, Zwitserland
Fluorouracile	Frankrijk
Flurablastin	Denemarken, Finland, Noorwegen, Zweden
Fluracedyl	België, Luxemburg, Maleisië, Nederland
Fluroblastin	Zuid-Afrika
Fluroblastine	België
Flurox	Mexico
Neofluor	Duitsland
Neoflur	Egypte
Oncofu	Argentinië
Ribofluor	Duitsland
Triosules	Argentinië

Literatuur : Fluorouracil

	type	publicatie
3	Artikel	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
5	Artikel	Stiles ML, Allen LV Jr, Prince SJ. Stability of deferoxamine mesylate, floxuridine, fluorouracil, hydromorphone hydrochloride, lorazepam, and midazolam hydrochloride in polypropylene infusion-pump syringes. Am J Health-Syst Pharm 1996 ; 53: 1583-1588.
33	Artikel	Baud-Camus F, Crauste-Manciet S, Klein E, Richard L, Brossard D. Stability of fluorouracil in polypropylene syringes and ethylene vinyl acetate infusion-pump reservoirs. Am J Health-Syst Pharm 1996 ; 53: 1457-1458.
39	Artikel	Farhang-Asnafi S, Callaert S, Barre J, Tillement JP, Thebault A. Influence of intravenous admixtures on the stability of the new solution of 5-fluorouracil. J Pharm Clin 1997 ; 16: 45-48.
40	Artikel	Dine T, Lebegue S, Benaji B, Gressier B, Segard V, Goudaliez F, Luyckx M, Brunet C, Mallevais ML, Kablan J, Cazin M, Cazin JC. Stability and compatibility studies of four cytostatic agents (fluorouracil, dacarbazine, cyclophosphamide and ifosfamide) with PVC infusion bags. Pharm Sci Communications 1994 ; 4: 97-101.
49	Artikel	Trissel LA, Martinez JF. Compatibility of granisetron hydrochloride with selected alkaline drugs. Am J Health-Syst Pharm 1995 ; 52: 208.
57	Artikel	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
81	Artikel	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Artikel	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
85	Artikel	Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 1716-1719.
91	Artikel	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
99	Artikel	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
110	Artikel	Vincke BJ, Verstraeten AE, El Eini DID, Mc Carthy TM. Extended stability of 5-fluorouracil and methotrexate solutions in PVC containers. Int J Pharm 1989 ; 54: 181-189.
138	Artikel	Corbrion V, Crauste-Manciet S, Allain P, Brossard D. Precipitation of fluorouracil in elastomeric infusers with a polyisoprene reservoir and in polypropylene syringes with an elastomeric joint. Am J Health-Syst Pharm 1997 ; 54: 1845-1848.
142	Artikel	Rochard EB, Barthes DMC, Courtois PY. Stability of fluorouracil, cytarabine, or doxorubicin hydrochloride in ethylene vinylacetate portable infusion-pump reservoirs. Am J Hosp Pharm 1992 ; 49: 619-623.
153	Artikel	Wang DP, Chang LC, Lee DK. Stability of fluorouracil-metoclopramide hydrochloride admixture. Am J Health-Syst Pharm 1995 ; 52: 98-99.
155	Artikel	Trissel LA, Martinez JF, Xu QA. Incompatibility of fluorouracil with leucovorin calcium or levoleucovorin calcium. Am J Health-Syst Pharm 1995 ; 52: 710-715.
156	Artikel	Barberi-Hayob M, Merlin JL, Vigneron M, Conroy T. Addition of heparin in 5-fluorouracil solution for portal vein infusion has no influence on its stability under clinically relevant conditions. Anticancer Drugs 1995 ; 6: 163-164.
163	Artikel	Sewell GJ, Allsopp M, Collinson MP, Tyrrell C, Prentice AJ, Copplestone JA. Stability studies on admixtures of 5-fluorouracil with carboplatin and 5-fluorouracil with heparin for administration in continuous infusion regimens. J Clin Pharm Ther 1994 ; 19: 127-133.
169	Artikel	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Artikel	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	Artikel	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Artikel	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Artikel	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
300	Artikel	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Artikel	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Artikel	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Artikel	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Artikel	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
411	Artikel	Woloschuk DMM, Wermeling JR, Pruemer JM. Stability and compatibility of fluorouracil and mannitol during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 2158-2160.
413	Artikel	Stewart CF, Fleming RA. Compatibility of cisplatin and fluorouracil in 0.9% sodium chloride injection. Am J Hosp Pharm 1990 ; 47: 1373-1377.
415	Artikel	Stiles ML, Allen LV, Tu YH. Stability of fluorouracil administered through four portable infusion pumps. Am J Hosp Pharm 1989 ; 46: 2036-2040.
431	Artikel	McRae MP, King JC. Compatibility of antineoplastic, antibiotic and corticosteroid drugs in intravenous admixtures. Am J Hosp Pharm 1975 ; 33: 1010-1013.
484	Artikel	Northcott M, Allsopp MA, Powell H, Sewell GJ. The stability of carboplatin, diamorphine, 5-fluorouracil and mitozantrone infusions in an ambulatory pump under storage and prolonged “in use” conditions. J Clin Pharm Ther 1991 ; 16: 123-129.
492	Artikel	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
513	Artikel	Xu QA, Trissel LA, Martinez JF. Stability and compatibility of fluorouracil with morphine sulfate and hydromorphone hydrochloride. Ann Pharmacotherapy 1996 ; 30: 756-761.
514	Artikel	Xu QA, Trissel LA, Martinez JF. Rapid loss of fentanyl citrate admixed with fluorouracil in polyvinyl chloride containers. Ann Pharmacotherapy 1997 ; 31: 297-302.
763	Artikel	Cohen MH, Jonhson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH. Drug precipitation within IV tubing : A potential hazard of chemotherapy administration. Cancer Treat Rep 1985 ; 69: 1325-1326.
840	Artikel	Biondi L, Nairn JG. Stability of 5-fluorouracil and flucytosine in parenteral solutions. Can J Hosp Pharm 1986 ; 39: 60-66.
842	Artikel	Pinguet F, Favre G, Canal P, Pujol A, Soula G. Stability of 5-fluorouracil to heat and light. J Pharm Clin 1990 ; 9: 155-158.
844	Artikel	Rochard E, Chapelle G, Bouquet S, Barthes D, Courtois PH. Stability of fluorouracil and cytarabine in ethylvinylacetate containers. J Pharm Clin 1989 ; 9: 31-35.
905	Artikel	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Artikel	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1026	Artikel	Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881.
1040	Artikel	Quebbeman EJ, Hamid AAR, Hoffman NE, Ausman RK. Stability of fluorouracil in plastic containers used for continuous infusion at home. Am J Hosp Pharm 1984 ; 41: 1153-1156.
1228	Artikel	Allen LV, Stiles ML. Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2. Am J Hosp Pharm 1981 ; 38: 380-381.
1325	Artikel	Hardin TC, Clibon U, Page CP, Cruz AB. Compatibility of 5-fluorouracil and total nutrition solutions. JPEN 1982 ; 6: 163-165.
1410	Artikel	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Artikel	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Artikel	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1475	Artikel	Martel P, Petit I, Pinguet F, Poujol S, Astre C, Fabbro M. Long-term stability of 5-fluorouracil stored in PVC bags and in ambulatory pump reservoirs. J Pharm Biomed Anal 1996 ; 14: 395-399.
1501	Artikel	Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M. Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials. Int J Pharm 1999 ; 185: 113-121.
1520	fabrikant	Etude de stabilité des médicaments en Ecoflac® B Braun 2001
1625	Artikel	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1812	Artikel	Fuhrman LC, Godwin DA, Davis RA. Stability of 5-fluorouracil in an extemporaneously compounded ophtalmic solution. Int J Pharm Compound 2000 ; 4, 4: 320-323.
1817	Artikel	Roberts S, Sewell GJ. Stability and compatibility of 5-fluorouracil infusions in the Braun Easypump®. J Oncol Pharm Practice 2003 ; 9: 109-112.
1842	Artikel	Sadjack A, Wintersteiger R. Compatibility of morphin, baclofen, floxuridine and fluorouracil in an implantable infusion pump. Arzneimittel Forschung 1995 ; 45: 93-98.
1925	Artikel	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Artikel	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Artikel	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
1998	Artikel	Allwood MC. Fluorouracil precipitate. Am J Health-Syst Pharm 1998 55: 1315-1316.
2009	Artikel	Trissel LA, Zhang Y. Physical and chemical stability of palonosetron hydrochloride with fluorouracil and with gemcitabine hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 2005, 9, 4: 320-322.
2130	Artikel	Lokiec F, Amirault P, Bonnans H, Gauzan MF, Sauvage N, Santoni J. Stabilité du mélange 5-fluoro-uracil-acide fonique : influence des concentrations, du contenant et de la forme de l’acide folinique. Bull Cancer 1999 ; 86, 11: 946-954.
2181	Artikel	Milano G, Renée N. Etude de compatibilité physicochimique 5- fluoro-uracile (nouvelle préparation française) - acide folinique. Bull Cancer 1995 ; 82: 189-195.
2262	Artikel	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2323	Artikel	Galanti L, Lebitasy M.P, Hecq J.D, Cadrobbi J, Vanbeckbergen D, Jamart J. Long-Term Stability of 5-Fluorouracil in 0.9% Sodium Chloride after Freezing, Microwave Thawing, and Refrigeration Can J Hosp Pharm 2009 ; 62, 1
3369	fabrikant	Levofolinate de sodium Medac - Résumé des caractéristiques du produits MEDAC France 2011
3474	fabrikant	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3531	fabrikant	Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014
3574	fabrikant	Ondansetron - Résumé des caractéristiques du produit Accord Healthcare France SAS 2013
3578	fabrikant	Cisplatin - Summary of Product Characteristics Accord Healthcare 2011
3580	fabrikant	Cytarabine Accord - Résumé des caractéristiques du produit Accord Healthcare France 2016
3634	fabrikant	Oxaliplatine (Oxaliplatine Accord®) - Résumé des caractéristiques du produit Accord Healthcare 2011
3637	fabrikant	Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics Hameln Pharmaceuticals 2014
3645	fabrikant	Doxorubicin - Summary of Product Characteristics Accord Healthcare 2014
3670	Artikel	Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30.
3873	Artikel	Tan X, Hu J. Incompatibility between irinotecan and fluorouracil injections Am J Health-Syst Pharm 2016 ; 73:755.
3948	Artikel	Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P . Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation. JPEN 2012 ;30. 416?424.
4568	Artikel	Closset M,Onorati S, Colsoul M.L,Goderniaux N,Bihin B, Jamart J, Soumoy L, Hecq J.D, Odou P, Galanti L. Long-term physico-chemical stability of 5-fluorouracile at standardised rounded doses (SRD) in MyFuser® portable infusion pump. Journal of Chemotherapy 2021
4735	Artikel	Closset M, Onorati S, Colsoul M-L, Goderniaux N, Bihin B, Jamart J, Soumoy L, Hecq J-D, Odou P, Galanti L. Long-term physicochemical stability of 5-fluorouracil at selected standardised rounded doses in polyolefin bags. J Oncol Pharm Practice 2023 ;29,8:1878 - 1883
4759	Poster	Ma NH, Charbonneau LF, Law S, Walker S. Stability of 5-fluorouracil at 4°C, 25°C, and 33°C stored in NiproSureFuser+ Ambulatory Balloon Infusers. Sunnybrook Healt Science Centre 2023

Mentions Légales